MUTATIONAL PROFILE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROME AT THE TIME OF PROGRESSION TO ACUTE LEUKEMIA

被引：0
|
作者：
Pedrote, B. [1 ]
Falantes, J. F. [1 ]
Carrillo, E. [1 ]
Calderon-Cabrera, C. [1 ]
Espigado, I [1 ]
Perez-Simon, J. A. [1 ]
机构：
[1] Hosp Univ Virgen Rocio, Seville, Spain
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PC-051
引用
收藏
页码：182 / 182
页数：1
相关论文
共 50 条
  • [21] MUTATIONAL PROFILE OF RELAPSE-RISK GROUPS IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS
    Prieto-Conde, M.
    Alcoceba, M.
    Jimenez, C.
    Garcia-Alvarez, M.
    Sarasquete, M. E.
    Balanzategui, A.
    Corral, R.
    Marin, L.
    Ramos, F.
    Godoy, A.
    Barez, A.
    Gutierrez, N. C.
    Garcia-Sanz, R.
    Gonzalez-Diaz, M.
    Chillon, M. C.
    HAEMATOLOGICA, 2017, 102 : 364 - 365
  • [22] The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome
    Isidori, Alessandro
    Ruzzo, Annamaria
    Loscocco, Federica
    Voso, Maria Teresa
    Graziano, Francesco
    Barulli, Sara
    Canestrari, Emanuele
    Volpe, Antonio
    Magro, Domenico
    Piccaluga, Pier Paolo
    Fuligni, Fabio
    Paolini, Stefania
    Ricciardi, Teresa
    Picardi, Paola
    Giacomini, Elisa
    Rocchi, Marco
    Magnani, Mauro
    Visani, Giuseppe
    BLOOD, 2013, 122 (21)
  • [23] Progression of a myelodysplastic syndrome with trisomy 8 to acute lymphoblastic leukemia
    Mishima, A
    Aoba, M
    Yamaji, S
    Taguchi, J
    Kanamori, H
    Motomura, S
    Mohri, H
    Okubo, T
    AMERICAN JOURNAL OF HEMATOLOGY, 1998, 58 (04) : 342 - 342
  • [24] PREDICTION OF DISEASE PROGRESSION USING MUTATIONAL SCREENING IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
    Belickova, M.
    Vesela, J.
    Votavova, H.
    Vostry, M.
    Jonasova, A.
    Zemanova, Z.
    Brezinova, J.
    Cermak, J.
    LEUKEMIA RESEARCH, 2017, 55 : S136 - S137
  • [25] GENOMIC CHARACTERIZATION OF PATIENTS WITH LOW-RISK ACUTE MYELOID LEUKEMIA (AML)
    Prieto-Conde, M. I.
    Jimenez, C.
    Alcoceba, M.
    Garcia-Alvarez, M.
    Sarasquete, M. E.
    Balanzategui, A.
    Hernandez-Ruano, M.
    Sebastian, E.
    Corral, R.
    Marn, L.
    Ramos, F.
    Godoy, A.
    Barez, A.
    Gutierrez, N. C.
    Garcia-Sanz, R.
    Gonzalez-Diaz, M.
    Chillon, M. C.
    HAEMATOLOGICA, 2016, 101 : 668 - 668
  • [26] Examining the safety and efficacy of imetelstat in low-risk myelodysplastic syndrome
    Thomas, Xavier
    EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (05) : 525 - 533
  • [27] Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies
    Trivedi, Gaurang
    Inoue, Daichi
    Zhang, Lingbo
    TRENDS IN MOLECULAR MEDICINE, 2021, 27 (10) : 990 - 999
  • [28] Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome
    E. Musch
    M. Malek
    A. Chrissafidou
    Annals of Hematology, 2003, 82 : 244 - 246
  • [29] Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome
    Ramon Gonzalez-Porras, Jose
    Cordoba, Iris
    Such, Esperanza
    Nomdedeu, Benet
    Vallespi, Teresa
    Carbonell, Felix
    Luno, Elisa
    Ardanaz, Maite
    Ramos, Fernando
    Pedro, Carme
    Gomez, Valle
    de Paz, Raquel
    Sanchez-Barba, Mercedes
    Sanz, Guillermo F.
    del Canizo, Consuelo
    CANCER, 2011, 117 (24) : 5529 - 5537
  • [30] Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome
    Musch, E
    Malek, M
    Chrissafidou, A
    ANNALS OF HEMATOLOGY, 2003, 82 (04) : 244 - 246
12345